2.09
-0.07(-3.24%)
Currency In USD
| Previous Close | 2.16 |
| Open | 2.33 |
| Day High | 2.79 |
| Day Low | 2.05 |
| 52-Week High | 2.79 |
| 52-Week Low | 0.66 |
| Volume | 13.65M |
| Average Volume | 2.67M |
| Market Cap | 137.69M |
| PE | -1.32 |
| EPS | -1.58 |
| Moving Average 50 Days | 1.66 |
| Moving Average 200 Days | 1.14 |
| Change | -0.07 |
If you invested $1000 in IO Biotech, Inc. (IOBT) since IPO date, it would be worth $140.26 as of August 18, 2025 at a share price of $2.195. Whereas If you bought $1000 worth of IO Biotech, Inc. (IOBT) shares 3 years ago, it would be worth $596.47 as of August 18, 2025 at a share price of $2.195.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
GlobeNewswire Inc.
Aug 11, 2025 12:00 PM GMT
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with
IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
GlobeNewswire Inc.
Aug 10, 2025 12:00 PM GMT
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline
IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 20, 2025 12:05 PM GMT
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that Mai-Britt Zocca, PhD, the company’